Article Text

PDF
Bevacizumab-based therapy for advanced small bowel adenocarcinoma
  1. H Tsang1,
  2. T Yau1,
  3. P L Khong2,
  4. R J Epstein1
  1. 1
    Department of Medicine, Queen Mary Hospital, Hong Kong
  2. 2
    Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong
  1. Dr T Yau, Room 405, Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong; the{at}netvigator.com

Statistics from Altmetric.com

Several articles in Gut have highlighted the predisposition to small bowel carcinogenesis caused by either mismatch repair gene mutations1 or chronic mucosal wounding by conditions such as Crohn’s disease2 or coeliac sprue.3 Small bowel damage of the latter kind is associated with induction of the proangiogenic peptide, vascular endothelial growth factor (VEGF),4 which is in turn accompanied by expression of proinflammatory cyclo-oxygenases and the wound healing cytokine transforming growth factor β.4 Since a similar growth factor expression profile is recognised in small bowel adenocarcinoma (SBA)5—an uncommon malignancy in which even the minority of resectable …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.